## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPE	ROVAL
OMB Number:	3235-0287
Estimated average	burden
haura par raapanaa	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Print or Type Responses)  1. Name and Address of Reporting Person*  Baskies Arnold M  (Last) (First) (Middle)  C/O ANIXA BIOSCIENCES, INC., 3150  ALMADEN EXPRESSWAY, SUITE 250  (Street)  SAN JOSE, CA 95118			A	2. Issuer Name and Ticker or Trading Symbol     Anixa Biosciences Inc [ANIX]     3. Date of Earliest Transaction (Month/Day/Year)     06/01/2021						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  _X_Director 10% Owner Officer (give title below) Other (specify below)  6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person					
			3150												
			4	4. If Amendment, Date Original Filed(Month/Day/Year)										_X_	
(City) (State) (Zip)			(Zip)	Table I - Non-Derivative Securities Acqu					Acquired	uired, Disposed of, or Beneficially Owned					
1.Title of Sec (Instr. 3)				2A. Deemed Execution Date, i any (Month/Day/Year		ite, if Co	Transode nstr. 8	(A) (I)	Securities Acqu of or Disposed of the str. 3, 4 and 5)  (A) or mount (D)	f (D) Own Tran	5. Amount of Securities Beneficial Owned Following Reported Transaction(s) (Instr. 3 and 4)		(C   F   C   O   (C	Ownership of orm:	Beneficial Ownership
								in this f	who respond orm are not re	quired to	respond (				74 (9-02)
								in this f		quired to	respond (				74 (9-02)
1. Title of Derivative Security (Instr. 3)	Price of Derivative	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transac Code	tion	5. Numb of Deriva Securitie Acquired or Dispo	er ative s	in this for a currer ired, Disponding, con 6. Date Exc	orm are not re tly valid OMB sed of, or Benef evertible securion reisable and Date	quired to control n	respond umber. ned d Amount	unless the	9. Number of Derivative Securities Beneficially Owned	10. Ownership Form of Derivative Security:	11. Natur of Indirec Beneficia Ownersh
Derivative Security	Conversion or Exercise Price of	Date	3A. Deemed Execution Date, if any	4. Transac Code	tion	1s, warra 5. Numb of Deriva Securitie Acquired	er ative s l(A) sed	in this for a current ired, Dispositions, con 6. Date Exe Expiration	orm are not re tly valid OMB sed of, or Benef evertible securion reisable and Date	required to control n ricially Own ties)  7. Title an of Underly Securities	respond umber. ned d Amount	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially	10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Natur of Indired Beneficia
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transac Code	tion	15. Numb of Deriva Securitie Acquired or Dispo of (D) (Instr. 3,	er ative s l(A) sed	in this for a current ired, Dispositions, con 6. Date Exe Expiration	orm are not rettly valid OMB sed of, or Benef evertible securit reisable and Date y/Year)  Expiration	required to control n ricially Own ties)  7. Title an of Underly Securities	respond umber. ned d Amount	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Natur of Indire Beneficia Ownersh

#### **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Baskies Arnold M C/O ANIXA BIOSCIENCES, INC. 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE, CA 95118	X					

### **Signatures**

/s/ Arnold M. Baskie	s	06/02/2021
**Signature of Reporting Person		Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan.
- (2) The options vest and become exercisable in twelve (12) equal monthly installments beginning June 30, 2021.

 $Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, {\it see} \ Instruction 6 for procedure. \\$ 

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.